NLRP3 and early-onset autosomal dominant Alzheimer disease: While targeting NLRP3‐driven immune response has been recognized as an effective therapeutic strategy to treat numerous inflammatory diseases, inhibiting MPC is also emerging as a promising approach for metabolic disorders, including type 2 diabetes, Alzheimer's disease and non‐alcoholic steatohepatitis.[28, 29, 49] Thus, UK5099 has the potential to treat these diseases with higher efficacy than approaches solely inhibiting one of these targets, which merits further exploration, though as highlighted below, derivatives of UK5099 that only target one of these molecules may be more desirable.